Semaglutide dose escalation and appetite loss: what the evidence shows

What's this video probably claiming?

Based on the caption, @jadekiwi is documenting a personal GLP-1 journey, specifically the move from 0.25mg to 0.5mg semaglutide at week three. The claims are fairly typical of this content genre: reduced appetite (evidenced by discarding meals), improved fasting blood glucose, and early weight loss of roughly 2kg in three weeks. The framing is anecdotal self-tracking, not medical advice, which is a meaningful distinction. What makes this worth examining isn't that the creator is lying, it's that personal response data gets read as generalizable experience by tens of thousands of viewers who are at different starting points, on different medications, or managing conditions the creator never mentions. The implicit message is: dose up, eat less, see results quickly. That deserves a harder look.

What does the science actually show?

The appetite suppression the creator describes is real and mechanistically documented. Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem, reducing gastric emptying and signaling satiety. The STEP 1 trial (Wilding et al., 2021, NEJM) showed that at the full 2.4mg maintenance dose, participants lost a mean 14.9% of body weight over 68 weeks. But that's the endpoint dose, not week three. At 0.5mg, the pharmacological effect is present but modest. The dose-escalation schedule exists precisely because appetite suppression and GI side effects scale with dose. Throwing out lunch at 0.5mg is consistent with early GI effects, not necessarily the full appetite-regulation mechanism at therapeutic levels. Blood glucose improvements at this stage are plausible but modest; the SUSTAIN-1 trial (Sorli et al., 2017, Diabetes, Obesity and Metabolism) showed meaningful HbA1c reductions primarily at 0.5mg and 1mg in T2D patients after 30 weeks, not three.

Where does the social media noise diverge from clinical reality?

The 2kg in three weeks figure will be the number people screenshot. Here's the problem: early weight loss on GLP-1 agonists is substantially fluid and glycogen depletion, not fat mass. Rapid initial drops are well documented and well misrepresented. A 2023 analysis by Kushner et al. in Obesity Reviews noted that body composition changes lag behind scale weight by several weeks during GLP-1 initiation. The other divergence is the implicit suggestion that skipping or discarding meals is a positive signal. Clinically, persistent nausea-driven food avoidance at 0.5mg can indicate the dose escalation was too fast for that individual, or that hydration and micronutrient intake are compromised. Gastroenterologists and endocrinologists managing these patients watch for this. TikTok does not. Self-titrating based on peer content without clinical oversight carries real risk, particularly for people with pre-existing GI conditions or disordered eating histories.

What should you actually know?

If you're on semaglutide or considering it, here are the things this kind of content routinely omits. First, the 0.25mg starting dose is not a therapeutic dose, it is a tolerability ramp. Appetite effects at that level are minimal by design. Second, meal skipping driven by nausea is not equivalent to voluntary caloric reduction and can mask inadequate protein and micronutrient intake. Third, blood glucose improvements self-reported without HbA1c or continuous monitoring context are almost impossible to interpret clinically. Fourth, individual response variation on GLP-1 therapy is substantial. The STEP trials showed a meaningful minority of participants lost less than 5% body weight at full dose. Finally, 2kg at week three tells you almost nothing about long-term trajectory. The SCALE trial (Pi-Sunyer et al., 2015, NEJM) with liraglutide showed that week-four responders and non-responders diverged significantly by week 56. Week three numbers are noise. Supervised titration with a prescribing clinician is what makes the difference.